Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications

Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi’s Sarcoma-Associated Herpesvirus Latent and Lytic Replications

ABSTRACT Oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically linked to primary effusion lymphoma (PEL), an aggressive and nontreatable malignancy commonly found in AIDS patients. In this study, we performed a high-throughput screening of 3,731 characterized compounds and identi...

Full description

Bibliographic Details
Main Authors: Marion Gruffaz, Shenghua Zhou, Karthik Vasan, Teresa Rushing, Qing Liu Michael, Chu Lu, Jae U. Jung, Shou-Jiang Gao
Format: Article
Language:English
Published: American Society for Microbiology 2018-07-01
Series:mBio
Subjects:
cytarabine
DNA/RNA syntheses
inhibition of latent and lytic replication
KSHV
latency-associated nuclear antigen (LANA) degradation
primary effusion lymphoma
Online Access:https://journals.asm.org/doi/10.1128/mBio.00756-18

Internet

https://journals.asm.org/doi/10.1128/mBio.00756-18

Similar Items